Clinical Trials Browser

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02130466 2022-08-01

MK-3475-022

Phase 1/2 Completed

184 enrolled 62 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase 2 Completed

177 enrolled 19 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Phase 2 Completed

77 enrolled 43 charts

Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT01750918 2021-10-29

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

Phase 1/2 Completed

166 enrolled 46 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT02124772 2021-07-14

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Phase 1/2 Completed

139 enrolled 42 charts 2 FDA

CNSMyeloid

Histiocytosis, Langerhans-Cell, Neoplasms, Neuroblastoma, Neurofibroma, Plexiform

NCT01597908 2021-02-24

COMBI-v

Phase 3 Completed

704 enrolled 13 charts

Dermatologic

Melanoma, Neoplasms

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Phase 3 Completed

423 enrolled 15 charts

Dermatologic

Melanoma

NCT01072175 2019-07-05

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Phase 2 Completed

430 enrolled 61 charts

Dermatologic

Melanoma, Neoplasms

NCT02039947 2019-05-21

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Phase 2 Completed

127 enrolled 17 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Tumor-Agnostic

Neoplasms

NCT02314143 2019-02-18

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Phase 2 Terminated

48 enrolled 20 charts

Dermatologic

Melanoma, Neoplasms

NCT01978236 2018-08-17

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Phase 2 Terminated

6 enrolled 9 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01245062 2018-04-05

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Phase 3 Completed

322 enrolled 24 charts

Dermatologic

Melanoma, Neoplasms

NCT01928940 2017-07-24

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Phase 2 Completed

12 enrolled 28 charts

Dermatologic

Melanoma

NCT01943864 2017-05-31

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

Phase 2 Completed

20 enrolled 27 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasms

NCT01362296 2014-07-11

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Phase 2 Completed

134 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00920140 2014-04-02

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Phase 2 Completed

97 enrolled 23 charts

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01037127 2014-03-31

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Phase 2 Completed

97 enrolled 18 charts

Dermatologic

Melanoma, Neoplasms

NCT01231581 2013-09-26

Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer

Phase 2 Completed

160 enrolled 14 charts

Tumor-Agnostic

Neoplasms

Clinical Trials

COMBI-AD

A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

CheckMate 9N9

COMBI-i

COMBI-APlus

OCEANMIST

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

MK-3475-022

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

COMBI-v

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

GSK1120212 Rollover Study

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer